Man Group’s Acceleron Pharma XLRN Stock Holding History

Man Group’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-49,096	Closed	-$8.45M	–	2210
2021 Q3	$8.45M	Buy	+49,096	New	+$6.42M	0.03%	638
2021 Q1	–	Sell	-15,797	Closed	-$2.02M	–	2067
2020 Q4	$2.02M	Sell	15,797 -66,307	-81%	-$7.77M	0.01%	1200
2020 Q3	$9.24M	Sell	82,104 -28,137	-26%	-$2.8M	0.04%	505
2020 Q2	$10.5M	Buy	110,241 +105,255	+2,111%	+$10.1M	0.05%	346
2020 Q1	$448K	Buy	+4,986	New	+$388K	﹤0.01%	1300
2019 Q4	–	Sell	-11,449	Closed	-$452K	–	1954
2019 Q3	$452K	Buy	+11,449	New	+$497K	﹤0.01%	1595
2018 Q4	–	Sell	-7,089	Closed	-$406K	–	2198
2018 Q3	$406K	Buy	+7,089	New	+$348K	﹤0.01%	1884

Man Group's XLRN Position: Q4 2021 in Review

Man Group sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 49,096 shares — an estimated $8.45M sold.

Man Group first reported a position in XLRN in Q3 2018 and held it in 7 quarters. The position peaked at $10.5M in Q2 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Man Group reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Man Group sold 49,096 Acceleron Pharma shares in Q4 2021, an estimated $8.45M.
Man Group first reported a position in Acceleron Pharma in Q3 2018 and held it in 7 quarters.
Man Group's Acceleron Pharma position peaked at $10.5M in Q2 2020.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Man Group's 13F filing for Q4 2021, filed 14 Feb 2022.